Browse AIM2

Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Activated inflammasomes can aggregate in the cytosol as speck-like particles.
Domain PF02760 HIN-200/IF120x domain
PF02758 PAAD/DAPIN/Pyrin domain
Function

Involved in innate immune response by recognizing cytosolic double-stranded DNA and inducing caspase-1-activating inflammasome formation in macrophages. Upon binding to DNA is thought to undergo oligomerization and to associate with PYCARD initiating the recruitment of caspase-1 precusrsor and processing of interleukin-1 beta and interleukin-18. Detects cytosolic dsDNA of viral and bacterial origin in a non-sequence-specific manner. Can also trigger PYCARD-dependent, caspase-1-independent cell death that involves caspase-8 (By similarity). Tumor suppressor which may act by repressing NF-kappa-B transcriptional activity.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002230 positive regulation of defense response to virus by host
GO:0002697 regulation of immune effector process
GO:0002831 regulation of response to biotic stimulus
GO:0009306 protein secretion
GO:0009615 response to virus
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0031334 positive regulation of protein complex assembly
GO:0031349 positive regulation of defense response
GO:0032088 negative regulation of NF-kappaB transcription factor activity
GO:0032459 regulation of protein oligomerization
GO:0032461 positive regulation of protein oligomerization
GO:0032611 interleukin-1 beta production
GO:0032612 interleukin-1 production
GO:0032651 regulation of interleukin-1 beta production
GO:0032652 regulation of interleukin-1 production
GO:0032731 positive regulation of interleukin-1 beta production
GO:0032732 positive regulation of interleukin-1 production
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0035456 response to interferon-beta
GO:0035458 cellular response to interferon-beta
GO:0035690 cellular response to drug
GO:0042493 response to drug
GO:0043254 regulation of protein complex assembly
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044089 positive regulation of cellular component biogenesis
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045862 positive regulation of proteolysis
GO:0050663 cytokine secretion
GO:0050688 regulation of defense response to virus
GO:0050691 regulation of defense response to virus by host
GO:0050701 interleukin-1 secretion
GO:0050702 interleukin-1 beta secretion
GO:0050704 regulation of interleukin-1 secretion
GO:0050706 regulation of interleukin-1 beta secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050716 positive regulation of interleukin-1 secretion
GO:0050718 positive regulation of interleukin-1 beta secretion
GO:0050792 regulation of viral process
GO:0051047 positive regulation of secretion
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051222 positive regulation of protein transport
GO:0051259 protein oligomerization
GO:0051607 defense response to virus
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0070269 pyroptosis
GO:0071356 cellular response to tumor necrosis factor
GO:0098542 defense response to other organism
GO:1903532 positive regulation of secretion by cell
GO:1904951 positive regulation of establishment of protein localization
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function -
Cellular Component GO:0044445 cytosolic part
GO:0061702 inflammasome complex
GO:0097169 AIM2 inflammasome complex
> KEGG and Reactome Pathway
 
KEGG hsa04621 NOD-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
Reactome R-HSA-168256: Immune System
R-HSA-622312: Inflammasomes
R-HSA-168249: Innate Immune System
R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
R-HSA-844615: The AIM2 inflammasome
Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AIM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AIM2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AIM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.3690.0419
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.6450.24
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.1820.35
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0990.838
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7490.53
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1670.402
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.4620.0754
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.6560.202
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.3440.32
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0970.407
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8610.651
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.050.858
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AIM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AIM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AIM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AIM2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AIM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AIM2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AIM2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAIM2
Nameabsent in melanoma 2
Aliases PYHIN4; Interferon-inducible protein AIM2
Chromosomal Location1q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AIM2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.